NP5.DE
Newron Pharmaceuticals SpA [NP5.DE] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
NP5.DE Stock Summary
Top 10 Correlated Stocks
NP5.DE
In the News
NP5.DE Financial details
Company Rating
Neutral
Market Cap
0
Income
-18.91M
Revenue
6.28M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
26
Optionable
No
Shortable
Yes
Earnings
-
P/E
-6.87
Forward P/E
0
PEG
-2.65
P/S
17.78
P/B
32.97
P/C
-
P/FCF
-
Quick Ratio
9.47
Current Ratio
10.79
Debt / Equity
-3.65
LT Debt / Equity
-3.24
-
-
EPS (TTM)
-1.06
EPS next Y
1385.87
EPS next Q
-
EPS this Y
16.67%
EPS next Y
-131151.31%
EPS next 5Y
-131151.31%
EPS last 5Y
3.13%
Revenue last 5Y
8.65%
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-5.4%
SMA50
141.3%
SMA100
351.52%
Inst Own
-
Inst Trans
-
ROA
-30%
ROE
-146%
ROC
-0.26%
Gross Margin
-
Oper. Margin
-214%
Profit Margin
-259%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.13-8.78
52W High
-28.25%
52W Low
+474%
RSI
49.98
Rel Volume
0.26
Avg Volume
11.06K
Volume
2.88K
Perf Week
-1.71%
Perf Month
-4.33%
Perf Quarter
325.19%
Perf Half Y
329.96%
-
-
-
-
Beta
-
-
-
Volatility
0.24%, 0.54%
Prev Close
0%
Price
5.74
Change
-3.04%
NP5.DE Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 0.23 | 0.39 | 0.29 | 0.32 | 0.34 | |
| Net income per share | -0.84 | -1.13 | -1.18 | -0.84 | -0.98 | |
| Operating cash flow per share | -0.9 | -1.24 | -0.87 | -0.64 | -0.62 | |
| Free cash flow per share | -0.9 | -1.25 | -0.88 | -0.64 | -0.62 | |
| Cash per share | 2.46 | 2.19 | 1.75 | 1.94 | 1.28 | |
| Book value per share | 3.07 | 2.06 | 0.97 | 0.17 | -0.79 | |
| Tangible book value per share | 3.07 | 2.06 | 0.97 | 0.17 | -0.79 | |
| Share holders equity per share | 3.07 | 2.06 | 0.97 | 0.17 | -0.79 | |
| Interest debt per share | 0 | 0.98 | 1.6 | 2.58 | 2.78 | |
| Market cap | 98.86M | 103.5M | 35.26M | 27.27M | 26.95M | |
| Enterprise value | 71.23M | 98.34M | 48.39M | 45.33M | 59.18M | |
| P/E ratio | -6.58 | -5.12 | -1.68 | -1.83 | -1.54 | |
| Price to sales ratio | 24.56 | 14.71 | 6.71 | 4.73 | 4.42 | |
| POCF ratio | -6.14 | -4.66 | -2.26 | -2.38 | -2.43 | |
| PFCF ratio | -6.12 | -4.65 | -2.26 | -2.38 | -2.43 | |
| P/B Ratio | 1.8 | 2.81 | 2.04 | 8.78 | -1.92 | |
| PTB ratio | 1.8 | 2.81 | 2.04 | 8.78 | -1.92 | |
| EV to sales | 17.7 | 13.97 | 9.2 | 7.87 | 9.71 | |
| Enterprise value over EBITDA | -4.78 | -5.07 | -2.82 | -3.86 | -4.44 | |
| EV to operating cash flow | -4.42 | -4.43 | -3.1 | -3.96 | -5.34 | |
| EV to free cash flow | -4.41 | -4.42 | -3.1 | -3.95 | -5.33 | |
| Earnings yield | -0.15 | -0.2 | -0.6 | -0.55 | -0.65 | |
| Free cash flow yield | -0.16 | -0.22 | -0.44 | -0.42 | -0.41 | |
| Debt to equity | 0.09 | 0.64 | 1.97 | 15.25 | -3.65 | |
| Debt to assets | 0.08 | 0.39 | 0.66 | 0.94 | 1.38 | |
| Net debt to EBITDA | 1.85 | 0.27 | -0.77 | -1.54 | -2.42 | |
| Current ratio | 13.9 | 10.71 | 5.5 | 10.79 | 5.65 | |
| Interest coverage | -267.46 | -36.54 | -8.07 | -4.23 | -3.37 | |
| Income quality | 1.07 | 1.1 | 0.74 | 0.77 | 0.63 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 1.28 | 0.91 | 0.94 | 0.61 | 0.58 | |
| Research and developement to revenue | 1.23 | 1.71 | 1.97 | 1.86 | 1.97 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | -0.01 | -0.01 | -0.01 | 0 | 0 | |
| Capex to depreciation | -0.85 | -0.25 | -0.16 | -0.1 | -0.09 | |
| Stock based compensation to revenue | 0.52 | 0.3 | 0.28 | 0.13 | 0.08 | |
| Graham number | 7.63 | 7.25 | 5.06 | 1.81 | 4.16 | |
| ROIC | -4.49 | -1.52 | -0.82 | 11.73 | -1.58 | |
| Return on tangible assets | -0.25 | -0.34 | -0.41 | -0.3 | -0.47 | |
| Graham Net | 2.18 | 0.88 | -0.15 | -0.72 | -1.59 | |
| Working capital | 55.23M | 54.35M | 30.98M | 35.77M | 23.45M | |
| Tangible asset value | 54.81M | 36.8M | 17.25M | 3.11M | -14.03M | |
| Net current asset value | 54.63M | 36.46M | 3.92M | -7.95M | -22.73M | |
| Invested capital | 0 | 0.46 | 1.53 | 13.87 | -3.25 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 1.69M | 1.78M | 1.84M | 1.39M | 1.71M | |
| Average inventory | 2.5K | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 305.67 | 616.27 | 1.58K | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 1.19 | 0.59 | 0.23 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.27 | -0.55 | -1.22 | -4.8 | 1.25 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2022-12-31 for Q4
| Metric | History | 2020-12-31 | 2021-06-30 | 2021-12-31 | 2022-06-30 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | 0 | 0 | 0 | 0 | 0 | |
| Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Cash per share | 0 | 0 | 0 | 0 | 0 | |
| Book value per share | 0 | 0 | 0 | 0 | 0 | |
| Tangible book value per share | 0 | 0 | 0 | 0 | 0 | |
| Share holders equity per share | 0 | 0 | 0 | 0 | 0 | |
| Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
| Market cap | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value | 13.13M | 15.55M | 18.06M | 25.58M | 32.24M | |
| P/E ratio | 0 | 0 | 0 | 0 | 0 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | 0 | 0 | 0 | 0 | 0 | |
| PFCF ratio | 0 | 0 | 0 | 0 | 0 | |
| P/B Ratio | 0 | 0 | 0 | 0 | 0 | |
| PTB ratio | 0 | 0 | 0 | 0 | 0 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | 0 | 0 | 0 | 0 | 0 | |
| EV to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| EV to free cash flow | 0 | 0 | 0 | 0 | 0 | |
| Earnings yield | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
| Debt to equity | 1.97 | 3.59 | 15.25 | -9.3 | -3.65 | |
| Debt to assets | 0.66 | 0.78 | 0.94 | 1.12 | 1.38 | |
| Net debt to EBITDA | 0 | 0 | 0 | 0 | 0 | |
| Current ratio | 5.5 | 7.9 | 10.79 | 8.84 | 5.65 | |
| Interest coverage | 0 | 0 | 0 | 0 | 0 | |
| Income quality | 0 | 0 | 0 | 0 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0 | 0 | 0 | 0 | 0 | |
| ROIC | 0 | 0 | 0 | 0 | 0 | |
| Return on tangible assets | 0 | 0 | 0 | 0 | 0 | |
| Graham Net | 0 | 0 | 0 | 0 | 0 | |
| Working capital | 30.98M | 24.34M | 35.77M | 29.98M | 23.45M | |
| Tangible asset value | 17.25M | 8.69M | 3.11M | -5.25M | -14.03M | |
| Net current asset value | 3.92M | -3.32M | -7.95M | -14.98M | -22.73M | |
| Invested capital | 1.53 | 3.1 | 13.87 | -8.48 | -3.25 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 0 | 0 | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0 | 0 | 0 | 0 | 0 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
NP5.DE Frequently Asked Questions
What is Newron Pharmaceuticals SpA stock symbol ?
Newron Pharmaceuticals SpA is a IT stock , located in Bresso of Milano and trading under the symbol NP5.DE
What is Newron Pharmaceuticals SpA stock quote today ?
Newron Pharmaceuticals SpA stock price is $5.74 today.
Is Newron Pharmaceuticals SpA stock public?
Yes, Newron Pharmaceuticals SpA is a publicly traded company.
Company Profile
- Volume Average 11.06K
- Employee 26
- CEO Prof. Stefan Weber
- Headquarters Bresso,MILANO,IT
- IPO Date 2006-12-12
-
Website
https://www.newron.com/ 
Newron Pharmaceuticals SpA operates as a biopharmaceutical company. The company is headquartered in Bresso, Milano and currently employs 24 full-time employees. The company focuses on the discovery and development of pharmaceutical products. The firm is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The firm undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.
